Recruiting

Testing immune cells to treat hard-to-treat lymphoma

Plain-English translation of NCT07162012 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new approach called anti-EBV autologous TCR-T cell injection for people with certain types of lymphoma that have stopped responding to standard treatments. Researchers take immune cells from your own body, reprogram them in the laboratory to recognize and fight your cancer, and then infuse them back into you. The study will measure whether this treatment is safe and whether it helps shrink your cancer.

Many patients with certain types of lymphoma do not respond well to existing treatments, and doctors need new options. This medication is designed to harness your own immune system to target cancer cells that carry a specific virus, offering hope for people who have limited choices.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with EBV-positive lymphoma that has either come back after remission or did not respond to prior treatments
you have a specific genetic marker (HLA-A11:01) that allows this treatment to work
you have received at least one prior treatment for your lymphoma
your blood tests and heart, kidney, and liver function are adequate enough to safely receive the treatment
you have at least one measurable cancer lesion visible on imaging or biopsy

You likely don't qualify if…

you are pregnant, planning to become pregnant, or unwilling to use contraception for 4 months after treatment
you have severely weakened organ function (very low blood counts, poor heart or kidney function)
you are unable to survive at least 3 months due to other health conditions
you have a performance status so poor that you cannot care for yourself or be active most of the day

What participation looks like

If you join this trial, doctors will collect immune cells from your blood through a procedure called apheresis. These cells will be sent to a laboratory where they are reprogrammed to recognize your cancer. After the cells are ready, you will receive an infusion of the treatment back into your body. You will then have regular clinic visits and blood tests to monitor your safety, how your body responds, and whether your cancer shrinks. The study will last several months, with close medical supervision to watch for any side effects.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai General Hospital, Shanghai